Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations to assess therapeutic responses.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Implementation of patient-reported outcomes in personalized lung cancer care: a qualitative study from the perspective of patients and health care providers.

Journal of patient-reported outcomes·2026

Same author

Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis.

The oncologist·2026

Same author

An agentic framework for autonomous scientific discovery in cancer pathology.

Nature medicine·2026

Same author

Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis.

The oncologist·2026

Same author

Global disparities in access to diagnostics and therapies for advanced non-small cell lung cancer: from discovery to delivery - a review.

Frontiers in oncology·2026

Same journal

Successful treatment with nab-paclitaxel and gemcitabine after FOLFIRINOX failure in a patient with metastasized pancreatic adenocarcinoma.

Onkologie·2013

Same journal

Metastatic germ cell tumour following renal transplantation.

Onkologie·2013

Same journal

miR-145 inhibits proliferation and invasion of esophageal squamous cell carcinoma in part by targeting c-Myc.

Onkologie·2013

Same journal

A meta-analysis of internal mammary lymph node metastasis in breast cancer patients.

Onkologie·2013

Same journal

Patient-related delay in presentation for cutaneous squamous cell carcinoma. A cross-sectional clinical study.

Onkologie·2013

Same journal

Treatment of primary breast cancer at the surgical unit of the Charité 1984-1998.

Onkologie·2013

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

[Current developments and perspectives in targeted therapies].

Nicolas Dickgreber¹, Rudolf M Huber, Martin Reck

¹Klinik für Pneumologie, Medizinische Hochschule Hannover, Deutschland.

|June 5, 2010

Summary

This summary is machine-generated.

Researchers are exploring new treatments for advanced non-small-cell lung cancer (NSCLC). This review covers maintenance therapies, including novel tyrosine kinase inhibitors (TKIs) and genetic markers, to improve patient outcomes.

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Related Experiment Videos

Last Updated: Jun 12, 2026

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Area of Science:

Oncology
Medical Research

Background:

Advanced non-small-cell lung cancer (NSCLC) presents significant treatment challenges.
Improving patient prognosis requires innovative therapeutic strategies.

Purpose of the Study:

To review current and emerging approaches for advanced NSCLC.
To discuss the role of maintenance therapy and novel targeted agents.
To explore the future potential of genetic markers in NSCLC treatment.

Main Methods:

Literature review of studies on maintenance therapy in advanced NSCLC.
Analysis of data on second-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).
Review of research on insulin-like growth factor receptor (IGFR) inhibitors, vascular-disrupting agents (VDAs), and multi-tyrosine kinase inhibitors (multi-TKIs) targeting vascular endothelial growth factor receptors (VEGFR).
Discussion of the role of genetic markers in NSCLC.

Main Results:

Maintenance therapy shows promise in prolonging survival after primary chemotherapy.
Second-generation EGFR-TKIs offer improved efficacy and safety profiles.
IGFR inhibitors, VDAs, and VEGFR-targeting multi-TKIs represent novel therapeutic avenues.
Genetic markers are increasingly important for personalized NSCLC treatment.

Conclusions:

Maintenance therapy is a crucial strategy for advanced NSCLC.
Targeted therapies, including novel TKIs and VDAs, are advancing treatment options.
The integration of genetic markers will likely personalize and improve future NSCLC management.